United Kingdom-based AstraZeneca has revealed positive overall survival (os) results from the Phase III CASPIAN trial with Imfinzi in first line extensive-stage small cell lung cancer (SCLC), it was reported on Friday.
An Independent Data Monitoring Committee conducted a planned interim analysis that revealed that the trial has met its primary endpoint by indicating a statistically-significant and clinically-meaningful improvement in overall survival in patients treated with Imfinzi in combination with standard-of-care etoposide and platinum-based chemotherapy options compared to chemotherapy alone.
CASPIAN is a randomised, open-label, multi-centre, global, Phase III trial of Imfinzi plus platinum-based chemotherapy options or the combination of Imfinzi, tremelimumab and chemotherapy, compared with chemotherapy alone as a first-line treatment for patients with extensive-stage SCLC. The trial will continue to the final analysis of overall survival for the combination of dual immune checkpoint blockade with chemotherapy. This combination includes tremelimumab, an anti-CTLA4 antibody and potential new medicine, with Imfinzi, an anti-PDL1 antibody, and chemotherapy.
The company is to submit these results for presentation at a forthcoming medical meeting.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review